Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients: Miami Saturday, August 2, 2025, 18:00 Hrs [IST] Pasith ...

Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

Idorsia Pharmaceuticals Ltd. has patented macrocyclic compounds acting as orexin OX2 receptor agonists reported to be useful for the treatment of obesity, pain, fatigue, inflammation, cognitive, sleep ...

Using parasiticides in cattle without considering the active ingredients in those products presents dangers for an operation.

The macrocyclic polyazomethine dyes 3a and 3b as well as macrocyclic polyazomethine pigments 4 and 5 present well pronounced fluorescent property in solid state (magenta luminescence under UV-light ...

Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting up-front, near-term payments and ...

SANTA CRUZ, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today ...

Our PDPS platform continues to prove extremely effective in discovering novel macrocyclic peptides for the targeted delivery of conjugated radionuclide payloads to tumors, and PeptiDream is focused on ...